Acadia in Pact With Biovail for Parkinson’s Drug

Acadia Pharmaceuticals Inc. said it entered into an agreement with a Biovail Corp unit to co-develop and commercialize its experimental drug to treat Parkinson’s disease psychosis in the United States and Canada.
Interactive Investor